Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis
NCT04767698 · Johns Hopkins University · PHASE2 · terminated · last registry update 2023-03-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The funding source decided to stop funding the study.” | – | Registry record, Johns Hopkins University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF13B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-02-09Results posted on the registry: Northwell Health, Belimumab + Placebo (NCT02347891)
- 2023-07-18Results posted on the registry: University of Alabama at Birmingham, Belimumab + Placebo (NCT03244059)
- 2023-05-26Phase 3 first posted: GlaxoSmithKline, Belimumab (NCT05878717)
- 2023-05-18Phase 3 first posted: Nanjing University School of Medicine, Methylprednisolone Injectable Suspension + Belimumab Injection (NCT05863936)
- 2023-04-03Results posted on the registry: Amgen, Rozibafusp Alfa + Placebo (NCT03156023)
- 2023-01-18Also stopped (withdrawn): xuna, Belimumab (Benlysta) (NCT05604742)
- 2023-01-09Results posted on the registry: University of Wisconsin, Madison, Belimumab (NCT03591380)
- 2023-01-09Also stopped (terminated): University of Wisconsin, Madison, Belimumab (NCT03591380)
- 2022-11-08Phase 3 first posted: Vera Therapeutics, Inc., Atacicept + Placebo (NCT05609812)
- 2022-05-24Results posted on the registry: Hospital for Special Surgery, New York, Belimumab + Mycophenolate Mofetil (NCT01670565)
- 2022-04-25Results posted on the registry: GlaxoSmithKline, Belimumab + Rituximab (NCT03312907)
- 2022-04-21Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Combination of Rituximab with subcutaneous belimumab + Combination of Rituximab with subcutaneous placebo (NCT05338190)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision